Support for managing and analyzing complex biological data related to cancer.
Official title: Administrative and Biostatistics
Funded at Wistar Institute · NIH-11085168 · Data updated 2026-11-12
This study is all about helping researchers work together better to understand Burkitt lymphoma and its related viruses, which could lead to new treatments that might help patients like you in the future.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 11, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $158,194 |
| NIH project number | 5P01CA269043-03 |
| Project ID | NIH-11085168 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit would include individuals affected by Burkitt lymphoma or those at risk due to genetic factors.
✕Less likely to help
Patients with unrelated cancers or conditions not associated with Burkitt lymphoma may not receive direct benefits from this research.
What this research studies
This research focuses on providing essential administrative and biostatistical support for various projects related to cancer, particularly Burkitt lymphoma and its associated viruses. It aims to facilitate communication and collaboration among researchers by managing data analysis, reporting results, and organizing meetings. The core team will ensure compliance with regulations and provide scientific leadership to enhance the understanding of biological pathways and networks. Patients may benefit indirectly through improved research outcomes and therapies developed from the findings.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and treatment options for cancers associated with Burkitt lymphoma and related viruses.
How similar studies have gone: Previous research has shown success in utilizing biostatistical approaches to improve cancer treatment outcomes, indicating a promising avenue for this project.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Lieberman, Paul M. — Wistar Institute
- Study coordinator: Lieberman, Paul M.
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.